Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1

Keyphrases

• 4-year-olds 100%
• Pegvisomant 100%
• Neurofibromatosis Type I 100%
• Neurofibromatosis Type 1 (NF-1) 100%
• Standard Deviation Score 60%
• Growth Hormone Deficiency 60%
• Insulin-like Growth factor-1 40%
• Insulin-like Growth Factor Binding protein-3 (IGFBP-3) 40%
• Treatment Duration 20%
• AIMS™ 20%
• Long-term Treatment 20%
• Visual Impairment 20%
• Fasting Plasma Glucose 20%
• Three-level 20%
• Current Treatment 20%
• Treatment Options 20%
• Thyroid Function 20%
• Glycated Hemoglobin 20%
• Rare Disorders 20%
• Adrenal Function 20%
• Somatostatin Analogs 20%
• Octreotide 20%
• Height Standard Deviation Score 20%
• Gonadal Function 20%
• Intracranial Tumor 20%
• Non-fasting 20%
• Serum Growth Hormone 20%
• Growth Velocity 20%
• Catch-up Growth 20%
• Height Velocity 20%
• Growth Hormone Receptor Antagonist 20%
• Target Height 20%
• Repeat Test 20%
• Pituitary Surgery 20%
• Pituitary Radiotherapy 20%
• Optic Pathway Glioma 20%

Medicine and Dentistry

• Pegvisomant 100%
• Neurofibromatosis Type I 100%
• Growth Hormone 80%
• Side Effect 40%
• Visual Impairment 20%
• Blood Glucose 20%
• Glycated Hemoglobin 20%
• Orphan Disorder 20%
• Adrenal Function 20%
• Growth Rate 20%
• Octreotide 20%
• Somatostatin Derivative 20%
• Thyroid Function 20%
• Acromegaly 20%
• Gonad Function 20%
• Growth Hormone Receptor 20%
• Hormone Receptor Blocking Agent 20%
• Intracranial Tumor 20%
• Pituitary Surgery 20%
• Optic Nerve Glioma 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Pegvisomant 100%
• Neurofibromatosis Type 1 100%
• Growth Hormone 80%
• Side Effect 40%
• Disease 20%
• Visual Impairment 20%
• Glycosylated Hemoglobin 20%
• Hormone Receptor Blocking Agent 20%
• Acromegaly 20%
• Octreotide 20%
• Somatostatin Derivative 20%
• Growth Hormone Receptor 20%
• Intracranial Tumor 20%
• Optic Nerve Glioma 20%